TY - JOUR T1 - Red blood cell alloimmunization among hospitalized patients: transfusion reactions and low alloantibody identification rate JO - Hematology, Transfusion and Cell Therapy T2 - AU - Pessoni,Lívia Lara AU - Ferreira,Marcos Antônio AU - Silva,Julles Cristiane Rodrigues da AU - Alcântara,Keila Correia de SN - 25311379 M3 - 10.1016/j.htct.2018.04.001 DO - 10.1016/j.htct.2018.04.001 UR - http://www.htct.com.br/en-red-blood-cell-alloimmunization-among-articulo-S253113791830083X AB - BackgroundUnexpected red blood cell alloantibodies can cause hemolytic transfusion reactions. In this study, the prevalence of alloimmunization, the rate of identification of alloantibodies and the rate of blood transfusion reactions among transfused patients were identified in a clinical emergency hospital in Brazil. MethodsTransfusions and clinical records of patients who had a positive indirect antiglobulin test between January and December 2013 were analyzed. ResultsOf 1169 patients who received blood transfusions, 28 had positive indirect antiglobulin tests, with one patient having two positive tests at different times, resulting in 29 positive tests during the period of this study. Alloantibodies were identified in 58.6% (17/29) of the cases. In 27.5% (8/29), identification was inconclusive and it was not possible to confirm alloimmunization. The rate of red blood cell alloimmunization was 1.71% (21/1169). Of 21 cases of alloimmunization, four (19%) were unidentified due to an unusual agglutination profile. All identified alloantibodies were clinically significant (10/17 anti-Rh, 5/17 anti-Kell and 2/17 anti-MNS). In two patients who had positive indirect antiglobulin tests, one had an unidentified alloantibody, and the other had an inconclusive test and developed a hemolytic transfusion reaction. ConclusionThe prevalence of clinically important red blood cell alloantibodies and hemolytic transfusion reactions among patients with unidentified alloantibodies suggests that specific laboratory techniques should be performed to identify alloantibodies in cases of pan-reactivity or autoantibodies to improve transfusion safety. ER -